Recently, our President and Managing Director, Jennifer Che, participated as a speaker at the HKSTP Market Discovery - BIO Connect event, hosted by HKSTP and InvestHK. This exclusive gathering brought together international biotech disruptors, offering them valuable insights into accessing the vast markets of Asia and beyond.

In her talk titled "Biotech Disruptors Benefit from HK IP," Jennifer highlighted the unique advantages Hong Kong offers from an intellectual property perspective. She discussed the rapidly developing IP ecosystem, including the homegrown original grant patent system and various tax and funding incentives that make the region an attractive hub for research and development. Additionally, she emphasized the expertise of local firms like Eagle IP, which are adept at navigating the complex IP challenges within the Greater Bay Area.

Our Past Events

Recommended Insights

US vs CN: Foreign Filing License Requirements

9 November 2022
In China, foreign filing requirements are generally very similar to the US — a foreign filing license is required if a foreign application is to be filed first for an invention made in the country. The Chinese equivalent to the US foreign filing license is called a confidentiality examination for foreign filing. According to Chinese […]

Foreign companies transferring IP out of China: things to know

25 October 2018
Inventions made in China Most foreign companies with R&D sites in China are aware of the fact that inventors having inventions made in China have to obtain permission before they can file patent applications outside of China for these Chinese inventions. It doesn’t matter if the owner of the business is a foreign entity. Patent […]

CHINA DIVISIONAL PATENT STRATEGY: Recent Judgment Narrows What Constitutes “Different Inventions” for Divisionals

6 December 2021
In China, patents applicants take advantage of a commonly-used divisional filing strategy to achieve a fine-tuned balance between protection scope and protection period (if used properly). Patent applicants (especially foreign applicants) widely welcome this well-established strategy, and up until now, have used it with much success. In fact, we recommend this strategy and have even […]

China Top 10 Patent Re-Examination and Invalidation Cases of 2020 CNIPA Upholds Bayer’s Rivaroxaban Patent

9 June 2021
The development of China’s approach to patents, especially those in the pharmaceutical and biotech space, has been fascinating to watch. Those of us who have practiced in the area for a long time have been frustrated by the Chinese patent office’s overly strict rules regarding patentability (e.g., high data support standard and refusal to consider […]
Top crossarrow-right